2017

150.00 rub.
Buy article
2017/№3

New possibilities of diagnostics and control of efficacy of drug therapy for chronic heart failure

Gyamdzhyan K. A., Kukes V. G.
Federal State Budgetary Educational Institution of Higher Education "I. M. Sechenov First Moscow State Medical University" of the Ministry of Health of the Russian Federation, Trubetskaya 8, Bldg. 2, Moscow 119991

Keywords: chronic heart failure, efficacy of drug therapy, galectin-3

DOI: 10.18087/rhfj.2017.3.2360

Background. Development of new biomarkers, which could be used as instruments for early detection of diseases to select drug therapy and monitor its efficacy, remains relevant. Aim. To assess the clinical value of measuring galectin-3 in patients with chronic heart failure. Materials and methods. The study included 53 patients (31 women and 22 men) with NYHA FC II-III CHF. Mean age of patients was 71 (95% CI, 68.99-74.37). The NYHA FC II CHF group consisted of 14 patients and the NYHA FC II CHF group consisted of 39 patients. Median baseline NT-proBNP level was 65.7 pmol/l and median baseline galectin-3 level was 8.37 pmol/l. Results. Increased galectin-3 levels correlated with reduced EF% (r=-0.26; p=0.04), increased creatinine (r=0.26, p=0.04), and increased plasma NT-proBNP (r=0.3; p=0.02). No significant correlation was found with other clinical indexes, such as systolic BP, diastolic BP, heart rate, BMI, 6-min walk test, left ventricular myocardial mass index, glucose concentration, total cholesterol, and GFR. A moderate correlation was observed for levels of NT-proBNP and plasma galectin-3 (r=0.3; p=0.02). Post-treatment decreases in galectin-3 were observed in 84.3% patients. Conclusion. Galectin-3 can be used as an auxiliary diagnostic biomarker for CHF.
  1. Lok DJA, Van Der Meer P, de la Porte PWB-A, Lipsic E, Van Wijngaarden J, Hillege HL et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99(5):323–8. DOI:10.1007/s00392-010-0125-y.
  2. de Boer RA, Lok DJA, Jaarsma T, van der Meer P, Voors AA, Hillege HL et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60–8. DOI:10.3109/07853890.2010.538080.
  3. de Boer RA, van der Velde AR, Mueller C, van Veldhuisen DJ, Anker SD, Peacock WF, et al. Galectin-3: A Modifiable Risk Factor in Heart Failure. Cardiovascular Drugs and Therapy. 2014;28(3):237–46. DOI:10.1007/s10557-014-6520-2.
  4. Liu Y-H, D’Ambrosio M, Liao T -d., Peng H, Rhaleb N-E, Sharma U et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. AJP: Heart and Circulatory Physiology. 2008;296(2):H404–12. DOI:10.1152/ajpheart.00747.2008.
  5. Kim H, Lee J, Hyun JW, Park JW, Joo H, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int. 2007;31(7):655–62. DOI:10.1016/j.cellbi.2006.11.036.
  6. Tang WHW, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108(3):385–90. DOI:10.1016/j.amjcard.2011.03.056.
  7. Ueland T, Aukrust P, Broch K, Aakhus S, Skårdal R, Muntendam P et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol. 2011;150(3):361–4. DOI:10.1016/j.ijcard.2011.05.081.
  8. Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail. 2012;14(1):74–81. DOI:10.1093/eurjhf/hfr151.
  9. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013;14(7):379–472. DOI:10.18087/rhfj.2013.7.1860 [Mareev V. Yu., Ageev F. T., Arutyunov G. P., Koroteev A. V., Mareev Yu. V., Ovchinnikov A. G. i dr. Naczional`ny`e rekomendaczii OSSN, RKO i RNMOT po diagnostike i lecheniyu XSN (chetverty`j peresmotr). Utverzhdeny` na Kongresse OSSN 7 dekabrya 2012 goda, na Pravlenii OSSN 31 marta 2013 i Kongresse RKO 25 sentyabrya 2013 goda. Zhurnal Serdechnaya Nedostatochnost`. 2013;14(7):379–472. DOI:10.18087/rhfj.2013.7.1860].
  10. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart. 2005;91(5):606–12. DOI:10.1136/hrt.2004.037762.
  11. Anand IS, Fisher LD, Chiang Y-T, Latini R, Masson S, Maggioni AP et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9):1278–83.
  12. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L et al. Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study. Circulation: Heart Failure. 2012;5(1):72–8. DOI:10.1161/CIRCHEARTFAILURE.111.963637.
  13. Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. European Journal of Heart Failure. 2013;15(10):1157–63. DOI:10.1093/eurjhf/hft075.
  14. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. European Journal of Heart Failure. 2013;15(5):511–8. DOI:10.1093/eurjhf/hfs205.
  15. van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217–24. DOI:10.1016/j.jacc.2006.03.061.
  16. Batlle M, Campos B, Farrero M, Cardona M, González B, Castel MA et al. Data on clinical characteristics of a heart failure patients’ cohort with reduced ejection fraction and analysis of the circulating values of five different heart failure biomarkers; high sensitivity troponin T, galectin-3, C-terminal propeptide of type I procollagen, soluble AXL and BNP. Data in Brief. 2016;9:876–82. DOI:10.1016/j.dib.2016.10.020.
  17. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948–54. DOI:10.1016/j.amjcard.2004.12.032.
  18. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12(4):200–10.
  19. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA et al. Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33(1):67–75. DOI:10.1161/ATVBAHA.112.300569.
  20. Deveci OS, Çelik AI, Ikikardes MF, Çagliyan CE, Özmen CA. Novel BioTarget in Treatment of Heart Failure: Changes in Serum Galectin-3 Levels after Spironolactone Therapy. J Hypertens. 2015;4(1):195–8. DOI:10.4172/2167-1095.1000195.
Gyamdzhyan K. A., Kukes V. G. New possibilities of diagnostics and control of efficacy of drug therapy for chronic heart failure. Russian Heart Failure Journal. 2017;18(3):185–189

To access this material please log in or register

Register Authorize
Ru En